After 1998, the number of reported cases of pure red cell aplasia (PRCA) increased dramatically among patients with chronic renal failure treated with exogenous erythropoietin, although the incidence of this condition has now abated. Antibody-positive PRCA has been most commonly associated with use of the Eprex Õ brand of epoetin-a. ESA (erythropoiesisstimulating agent)-associated PRCA remains rare, and suspected cases should undergo a thorough diagnostic work-up before laboratory testing for anti-ESA antibody-positive status. This article provides an overview of the recent history and growing understanding of ESA-associated PRCA together with current approaches to the management of this rare side effect of an otherwise valuable therapy.
Introduction
The past few years have seen the emergence of unprecedented cases of pure red cell aplasia (PRCA) associated with the use of erythropoiesis-stimulating agents (ESAs) in the management of anaemia of chronic renal failure. Until reports in February and May of 2002 suggesting that renal patients treated with a particular brand of epoetin (EPO)-a, Eprex Õ , were experiencing PRCA associated with anti-erythropoietin antibodies, drug-induced PRCA was considered an extremely rare and unusual occurrence [1] [2] [3] .
PRCA, although still uncommon, is a potentially life-threatening condition characterized by severe anaemia and requiring management with frequent blood transfusions. The reported increase in cases of PRCA linked with the use of Eprex Õ has fuelled research into the possible causes and sources of ESAassociated PRCA (ESA-PRCA) and has necessitated new approaches to the management of patients who produce autoantibodies to a therapy that, for the vast majority of patients, continues to offer massive benefits.
This overview considers the history of ESA-PRCA, provides pointers to the diagnosis and investigation of suspected cases of ESA-PRCA, and briefly reviews current theories and hypotheses regarding the emergence of this condition. It also offers some guidance on possible treatment strategies for patients who have developed antibody-mediated PRCA.
History of ESA-PRCA in chronic renal failure
In Europe, there are currently three types of ESA available for the correction of anaemia of chronic renal failure: epoetin-a, epoetin-b and darbepoetin-a. In contrast to the other two ESAs, however, more than one commercial brand of epoetin-a is available worldwide. The first report that a particular epoetin-a product appeared to be causing cases of PRCA was swiftly followed by FDA data highlighting a growing trend in the number of cases of PRCA recorded in association with use of ESA among renal patients [1, 2] . The FDA Medwatch data published in May 2002 suggested that some 141 treatment-associated cases of antibody-positive PRCA had emerged over a period of 2-3 years, the vast majority of which were linked to the use of Eprex Õ [2] . [4] [5] [6] .
Despite the widespread use of ESAs in the anaemia of cancer and other types of anaemia, virtually all cases of antibody-positive PRCA have occurred in patients with renal anaemia. It appears that ESA-PRCA occurs within a median time of 11 months from first exposure to an ESA, although cases show emergence of this adverse effect ranging from between 2 months to 5 years after the first use of Eprex Õ . The characteristics of PRCA or erythroblastopenia (red cell agenesis) are well defined [7] . Patients with ESA-PRCA experience the abrupt development of severe anaemia refractory to treatment. Haemoglobin (Hb) decreases at a rate of $0.1 g/dl/day, or $1 g/dl/week, such that patients require repeated red blood cell (RBC) transfusions-typically $4 units of packed RBCs per month.
In diagnosing this condition, severe anaemia unresponsive to ESA therapy is the first indicator of a potential problem. Serum ferritin is greatly elevated and patients with PRCA experience functional iron deficiency. Haematological investigation of these patients usually reveals reticulocytopenia (<10 000 cells/ml), although white cell and platelet counts are generally normal. Bone marrow histology in a patient with PRCA usually shows normal cellularity, although patients may show an almost complete eradication of erythroblasts, (with <5% cellularity devoted to erythroblasts) ( Figure 1 ). The final feature in the diagnosis of ESA-PRCA is a positive test for neutralizing anti-EPO antibodies.
Clinical algorithm for suspected cases of ESA-PRCA
Since the recognition of ESA-PRCA as a clinical phenomenon distinct from viral PRCA and other forms of drug-associated PRCA, there has been a growing demand for patient antibody testing in suspected cases of serious anaemia during ESA therapy. In any renal patient showing a rapid fall in Hb levels during long-term treatment with ESA, it is essential to eliminate other potential causes of anaemia before assuming PRCA. A reticulocyte count can provide a quick indication of erythropoietic activity in the bone marrow and, if counts are <10 Â 10 9 /l, treatment with all ESAs should be stopped until the cause of anaemia has been established. Although a positive test for anti-EPO antibodies provides the definitive diagnosis of ESA-PRCA, it is suggested that patients suspected of having this condition should undergo a diagnostic work-up as described in Figure 2 [7] .
In particular, only patients with severe resistance to ESA should be viewed as potential PRCA cases, and testing for antibodies should be among the last of the assessments performed in establishing PRCA.
Assays for the detection of anti-EPO antibodies include a highly sensitive radioimmune precipitation assay (RIPA), enzyme-linked immunosorbent assay (ELISA) detection and the BIACORE immunoassay. Immunoassays should be complemented by bioassays that confirm the neutralizing properties of the anti-EPO antibodies. Bioassays generally employ cultured cell lines derived from bone marrow tissue [colony-forming unit-erythroid cells (CFU-E)] or an erythropoietic cell line such as UT-7 cells.
Explaining the increase in PRCA incidence
A number of theories have been expounded to account for the rise in incidence of PRCA observed in the past few years and linked with the use of Eprex Õ . While no single answer has emerged as to why ESAs have become immunogenic, a number of possibilities have been ruled out and a number of clear correlations have been identified.
The rise in PRCA incidence does not simply reflect an increase in reporting of this rare side effect, and studies have shown that there is no link between PRCA and the presence of underlying renal disease or a patient's human leukocyte antigen (HLA) tissue type. Medical practice did not change over the period during which higher numbers of PRCA cases appeared, and no new treatments were introduced for the management of chronic anaemia. Furthermore, it has been shown that anti-EPO antibodies form against the protein component of erythropoietins and are not linked to differences in the carbohydrate moieties found in different therapeutic ESA preparations indicated for the management of anaemia.
However, a change in the formulation of Eprex Õ in 1998, when human serum albumin (HSA) was removed as a stabilizer, principally due to concerns in Europe over the risk of Creutzfeldt-Jakob prions in bloodderived products, did coincide with an upsurge in the number of reported cases of PRCA ( Table 1 ). The removal of HSA from Eprex Õ is considered to be an important contributory factor to a decrease in product stability, which in turn increases the likelihood of immunogenicity. The manufacturers of Eprex Õ suggested a link between greater use of s.c. drug administration and the rise in PRCA cases [8, 9] . It was suggested that an ESA delivered through the skin could indeed promote the chances of eliciting an immune response and the production of low-affinity IgG1 and IgG4 antibodies when compared with intravenous (i.v.) drug administration. However, the route of administration alone cannot account for the Eprex Õ -associated-PRCA cases, since over the same period of case reporting there was no evidence that s.c. administration of other ESAs was associated with a higher rate of PRCA [3] . Increasingly, it is thought that a combination of effects could account for the Eprex Õ -associated rise in PRCA. Removal of HSA, a break in the cold storage chain, and greater use of the s.c. route coincident with a decrease in product stability could in part explain an exacerbation of immune reactivity to exogenous ESA formulated as Eprex Õ . The 'micelle hypothesis' has also been suggested to explain the greater immunogenicity of Eprex Õ . In simple terms, this hypothesis proposes that the polysorbate 80 stabilizers in Eprex Õ associate with free epoetin-a to form micelles-conglomerations of Eprex Õ molecules and polysorbate molecules-and that these micelles effectively increase exposure of the ESA to surface proteins involved in triggering antibody responses [10] . Another hypothesis gathering increasing evidence is that rubber-derived leachates previously contained in the plungers of pre-filled syringes of 
Managing ESA-PRCA
Until such time as a complete explanation is found for the Eprex Õ -related rise in cases of PRCA, it is essential that clinicians learn to manage cases of ESA-PRCA.
Antibodies generated against ESA cross-react with endogenous and exogenous EPO and mandate that treatment with ESA of any brand is immediately discontinued in patients with PRCA. As described earlier, these patients then often require repeated RBC transfusions to prevent severe and life-threatening anaemia. Immunosuppressant therapy with corticosteroids and cyclophosphamide, or cyclosporin, can be used to control antibody formation [11] , but there is still uncertainty over whether renal patients with a history of PRCA can be re-challenged with ESA therapy once antibodies to ESA have subsided. Recently, however, there have been reports of five cases of ESA-associated PRCA in which re-challenge has been successful [12] [13] [14] .
Conclusions
The unexpected appearance of ESA-PRCA in recent years has challenged nephrologists and haematologists involved in the care of patients with anaemia and renal disease. Although much has been learnt about this unwanted adverse effect of an otherwise valuable therapy, many questions remain about PRCA. The exact causes and mechanisms of immunogenicity against ESAs continue to be subjects of active research and, in time, more may be understood about the occurrence of anti-ESA antibodies in patients exposed to these agents and whether such antibodies are always neutralizing. In terms of the clinical management of PRCA, there is continued debate over the optimal immunosuppressive regimen and whether re-challenge with ESAs is successful in the long term. However, until the results of research reveal more about the pathophysiology and immunology of PRCA, it is important to remember that ESA-PRCA continues to be a rare occurrence relative to the massive clinical benefits provided by ESAs in the management of renal anaemia [15] .
